Skip to main content

Table 2 Relative Dose Intensity (RDI), patients completing all cycles of chemotherapy and months of chemotherapy by regimen

From: Adjuvant chemotherapy for stage III colon cancer: relative dose intensity and survival among veterans

Outcomes

Total

5-FU/LV

Oxaliplatin plus 5-FU/LV

Oxaliplatin plus Capecitabine

Capecitabine Monotherapy

Mixed/Othera

 

N = 367

N = 113

N = 126

N = 20

N = 46

N = 62

Patients completing ≤70% of RDI, n (col%)

122 (33.2)

35 (31.0)

25 (19.8)

11 (55.0)

30 (65.2)

21 (33.9)

Patients completing >70% of RDI, n (col%)

206 (56.1)

70 (61.9)

90 (71.4)

8 (40.0)

14 (30.4)

24 (38.7)

Missing or unknown, b n (col%)

39 (10.6)

8 (7.1)

11 (8.7)

1 (5.0)

2 (4.3)

17 (27.4)

RDI (%), median (IQR)

82.3 (49.7, 97.5)

96.7 (52.0, 100)

86.1 (70.9, 96.3)

62.2 (46.9, 81.4)

51.2 (29.2, 72.1)

68.8 (42.8, 90.2)

Patients completing all cycles (N = 348), n (row%)

191 (54.9)

79 (73.8)

71 (58.2)

6 (30.0)

18 (40.0)

17 (31.5)

Months of chemotherapy, median (IQR)

5.4 (4.3, 6.2)

5.2 (4.5, 6.6)

5.6 (4.9, 6.1)

4.5 (3.1, 5.6)

4.9 (2.1, 5.6)

5.5 (3.6, 6.4)

  1. IQR = interquartile range (25th percentile, 75th percentile).
  2. a“Mixed/other” includes patients who switched regimens and those who received a chemotherapy regimen not listed.
  3. b39 (10.6%) categorized as missing because the regimen was not standard, or regimen data were missing. Therefore, RDI could not be calculated.
  4. Note: P < 0.0001 for the difference across regimens in categorical variables of RDI and patients completing all cycles of chemotherapy using Fisher exact tests and Chi-square tests, respectively; P < 0.001 for differences across regimens in continuous RDI, and P = 0.007 for differences in length of chemotherapy using Kruskal-Wallis tests.
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us